Provided by Tiger Trade Technology Pte. Ltd.

Senti Biosciences, Inc.

1.10
+0.138314.38%
Post-market: 1.09-0.0100-0.91%19:58 EDT
Volume:946.75K
Turnover:1.01M
Market Cap:34.26M
PE:-0.40
High:1.13
Open:1.02
Low:1.00
Close:0.9617
52wk High:5.10
52wk Low:0.7702
Shares:31.14M
Float Shares:14.58M
Volume Ratio:10.56
T/O Rate:6.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7326
EPS(LYR):-2.7326
ROE:-218.08%
ROA:-48.89%
PB:6.13
PE(LYR):-0.40

Loading ...

Senti Bio CEO Timothy Lu to present logic-gated NK cell therapy at AACR meeting

Reuters
·
Apr 13

BRIEF-Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026 - SEC Filing

Reuters
·
Apr 02

Senti Biosciences plans tax-free holding company reorganization by April 16

Reuters
·
Apr 02

Senti Bio study in Cell Systems advances NOT-gated CAR design for T and NK therapies

Reuters
·
Apr 01

Senti Biosciences Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 30

Chardan Cuts Price Target on Senti Biosciences to $11 From $13, Keeps Buy Rating

MT Newswires Live
·
Mar 30

Senti Biosciences Q4 EPS $(0.53) Misses $(0.48) Estimate, Sales $22.000K Miss $666.667K Estimate

Benzinga
·
Mar 27

Senti Biosciences Q4 revenue misses analyst estimates

Reuters
·
Mar 27

BRIEF-Senti Biosciences Q4 Net Income USD -14.467 Million

Reuters
·
Mar 27

Senti Biosciences Q4 EPS USD -0.53

THOMSON REUTERS
·
Mar 27

Senti Biosciences Q4 Revenue USD 22 Thousand

THOMSON REUTERS
·
Mar 27

Press Release: Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Dow Jones
·
Mar 27

Senti Biosciences to present SENTI-202 Phase 1 data at 11th Annual Innate Killer Conference

Reuters
·
Mar 23

Senti Biosciences Inc expected to post a loss of 41 cents a share - Earnings Preview

Reuters
·
Mar 17

Senti Biosciences CEO Timothy Lu to Present at Leerink Partners Global Healthcare Conference

Reuters
·
Mar 03

Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

Reuters
·
Feb 24

Senti Biosciences Joins Cell & Gene Live Virtual Event on Emerging Cell Therapy Technologies

Reuters
·
Feb 20

BRIEF-Senti Biosciences Completes Enrollment In Phase 1 Clinical Trial Of Senti-202

Reuters
·
Feb 11

Senti Biosciences Completes Phase 1 Enrollment for SENTI-202 in Relapsed or Refractory AML

Reuters
·
Feb 11

Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of Senti-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R Aml)

THOMSON REUTERS
·
Feb 11